利拉鲁肽:治疗2型糖尿病的新选择

Future Prescriber Pub Date : 2008-08-08 DOI:10.1002/fps.10

Milan K Piya, Abd A Tahrani, Anthony H Barnett

{"title":"利拉鲁肽:治疗2型糖尿病的新选择","authors":"Milan K Piya, Abd A Tahrani, Anthony H Barnett","doi":"10.1002/fps.10","DOIUrl":null,"url":null,"abstract":"Type 2 diabetes mellitus (T2DM) is a global epidemic with an expected prevalence of 380 million in 2025 worldwide1 and over 2.5 million by 2010 in the UK.2 Diabetes is a progres-sive disease which leads to macro and microvascular complications and reduced life expectancy.2 Furthermore, diabetes-related complications have been shown to worsen patients' quality of life.3,4 Copyright © 2008 John Wiley & Sons, Ltd.","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"9 2","pages":"6-12"},"PeriodicalIF":0.0000,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.10","citationCount":"3","resultStr":"{\"title\":\"Liraglutide: a new option in the management of type 2 diabetes\",\"authors\":\"Milan K Piya, Abd A Tahrani, Anthony H Barnett\",\"doi\":\"10.1002/fps.10\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Type 2 diabetes mellitus (T2DM) is a global epidemic with an expected prevalence of 380 million in 2025 worldwide1 and over 2.5 million by 2010 in the UK.2 Diabetes is a progres-sive disease which leads to macro and microvascular complications and reduced life expectancy.2 Furthermore, diabetes-related complications have been shown to worsen patients' quality of life.3,4 Copyright © 2008 John Wiley & Sons, Ltd.\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"9 2\",\"pages\":\"6-12\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.10\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.10\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.10","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Liraglutide: a new option in the management of type 2 diabetes

Type 2 diabetes mellitus (T2DM) is a global epidemic with an expected prevalence of 380 million in 2025 worldwide¹ and over 2.5 million by 2010 in the UK.² Diabetes is a progres-sive disease which leads to macro and microvascular complications and reduced life expectancy.² Furthermore, diabetes-related complications have been shown to worsen patients' quality of life.^3,4 Copyright © 2008 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量

期刊最新文献

Promising new drugs and drug targets for HIV treatment Treatment of rheumatoid arthritis: current and future Lurasidone: new development for the treatment of psychosis Sunovion: innovative medicines for areas of unmet clinical need Role and cost effectiveness of bariatric surgery in T2DM